Aptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last year
PremiumThe FlyAptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last year
6d ago
Aptose Biosciences (APTO) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Aptose Biosciences (APTO) Q4 Earnings Cheat Sheet
11d ago
Aptose Biosciences Regains Nasdaq Bid Price Compliance
Premium
Company Announcements
Aptose Biosciences Regains Nasdaq Bid Price Compliance
17d ago
Aptose Biosciences Advances TUSCANY Trial Dosage Escalation
PremiumCompany AnnouncementsAptose Biosciences Advances TUSCANY Trial Dosage Escalation
1M ago
Aptose Biosciences approved to escalate dose in Phase 1/2 AML trial
Premium
The Fly
Aptose Biosciences approved to escalate dose in Phase 1/2 AML trial
1M ago
Aptose Biosciences Announces Reverse Share Split
Premium
Company Announcements
Aptose Biosciences Announces Reverse Share Split
1M ago
Aptose Biosciences Establishes $25M Equity Facility
PremiumCompany AnnouncementsAptose Biosciences Establishes $25M Equity Facility
2M ago
Promising Results from Aptose Biosciences’ TUSCANY Trial Boost Joseph Pantginis’ Buy Rating
Premium
Ratings
Promising Results from Aptose Biosciences’ TUSCANY Trial Boost Joseph Pantginis’ Buy Rating
2M ago
Promising Early Results from Aptose’s TUSCANY Trial in AML Treatment
Premium
Company Announcements
Promising Early Results from Aptose’s TUSCANY Trial in AML Treatment
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100